The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor

Platelets

Volumn 23, Issue 8, 2012, Pages 617-625

  Tournoij, Erik ^a   Koekman, C Arnold ^a   Du, Vivian X ^a   Roest, Mark ^a   Ruijtenbeek, Rob ^b   Moll, Frans L ^a   Akkerman, Jan Willem N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PamGene International BV   (Netherlands)

Author keywords

Clopidogrel; Ephrin receptors; P2Y12 receptor; Platelets; Tyrosine kinases

Indexed keywords

ADENOSINE DIPHOSPHATE; BENZOIC ACID DERIVATIVE; COLLAGEN; EPHRIN A4; EPHRIN B1; EPHRIN RECEPTOR A4; PROTEIN TYROSINE KINASE; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; LIGAND; PHOSPHOPROTEIN; PURINERGIC P2 RECEPTOR ANTAGONIST;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR BLOCKING; SECOND MESSENGER; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; SECRETORY VESICLE; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; EPHRIN-A4; HUMANS; LIGANDS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PROTEIN ARRAY ANALYSIS; PROTEIN-TYROSINE KINASES; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTOR CROSS-TALK; RECEPTOR, EPHA4; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y12; SECRETORY VESICLES; SIGNAL TRANSDUCTION;

EID: 84868619322     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.645924     Document Type: Article

References (32)

1. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006;4:2317-2326.
2. Gachet C. Regulation of platelet functions by P2 receptor. Annu Rev Pharmacol Toxicol 2006;46:277-300.
3. Cattaneo M. Disorders of platelet function. Abnormalities of the platelet P2 receptors. Pathophysiol Haemost Thromb 2006;35: 10-14.
4. Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WG, Bentley D, Burns P, Coffey A, Deloukas P, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009;114:1405-1416.
5. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
6. Yan R, Wang Z, Yuan Y, Cheng H, Dai K. Role of cAMPdependent protein kinase in the regulation of platelet procoagulant activity. Arch Biochem Biophys 2009;485:41-48.
7. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002;3:475-486.
8. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol Cancer Res 2008;6:1795-1806.
9. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52.
10. Lackmann M, Boyd AW. Eph, a protein family coming of age: More confusion, insight, or complexity? Sci Signal 2008;1:re2.
11. Abdul-Aziz NM, Turmaine M, Greene ND, Copp AJ. EphrinA-EphA receptor interactions in mouse spinal neurulation: implications for neural fold fusion. Int J Dev Biol 2009;53:559-568.
12. Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, Iwakura Y, Suda T, Matsuo K. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 2009;284:14637-14644.
13. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K, Wurst W, Nagamatsu S, Lammert E. EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell 2007;129:359-370.
14. Herbert SP, Huisken J, Kim TN, Feldman ME, Houseman BT, Wang RA, Shokat KM, Stainier DY. Arterial-venous segregation by selective cell sprouting: An alternative mode of blood vessel formation. Science 2009;326:294-298.
15. Prevost N, Woulfe D, Tanaka T, Brass LF. Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc Natl Acad Sci USA 2002;99:9219-9224.
16. Prevost N, Woulfe DS, Jiang H, Stalker TJ, Marchese P, Ruggeri ZM, Brass LF. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci USA 2005;102:9820-9825.
17. Prevost N, Woulfe DS, Tognolini M, Tanaka T, Jian W, Fortna RR, Jiang H, Brass LF. Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1. Blood 2004;103:1348-1355.
18. Lewandrowski U, Wortelkamp S, Lohrig K, Zahedi RP, Wolters DA, Walter U, Sickmann A. Platelet membrane proteomics: A novel repository for functional research. Blood 2009;114: E10-e19.
19. Dittrich M, Birschmann I, Mietner S, Sickmann A, Walter U, Dandekar T. Platelet protein interactions: Map, signaling components, and phosphorylation groundstate. Arterioscler Thromb Vasc Biol 2008;28:1326-1331.
20. Tucker KL, Kaiser WJ, Bergeron AL, Hu H, Dong JF, Tan TH, Gibbins JM. Proteomic analysis of resting and thrombinstimulated platelets reveals the translocation and functional relevance of HIP-55 in platelets. Proteomics 2009;9:4340-4354.
21. Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, Roth GP, Pasquale EB. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 2008;283:29461-29472.
22. Korporaal SJ, van Eck M, Adelmeijer J, Ijsseldijk M, Out R, Lisman T, Lenting PJ, Van Berkel TJ, Akkerman JW. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol 2007;27:2476-2483.
23. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R. Peptide micro-arrays for detailed, high-throughput substrate identification, kinetic characterisation and inhibition studies on Protein Kinase A. Anal Biochem 2009;387:150-161.
24. Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, Heck AJ, den Hertog J. Protein-tyrosine kinase activity profiling in knock down zebrafish embryos. PLoS ONE 2007;2:e581.
25. de Haas CJ, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, Lisman T. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alphabeta. J Thromb Haemost 2009;7:1867-1874.
26. Jakobs KH, Wieland T. Evidence for receptor-regulated phosphotransfer reactions involved in activation of the adenylate cyclase inhibitory G protein in human platelet membranes. Eur J Biochem 1989;183:115-121.
27. Lanza F, Beretz A, Stierlé A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988;255:H1276-1288.
28. Remijn JA, Wu YP, Jeninga EH, Ijsseldijk MJ, van Willigen G, de Groot PG, Sixma JJ, Nurden AT, Nurden P. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002;22:686-691.
29. Qin H, Shi J, Noberini R, Pasquale EB, Song J. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J Biol Chem 2008;283:9473-9484.
30. White JG, Witkop CJ. Effects of normal and aspirin platelets on defective secondary aggregation in the Hermansky-Pudlak syndrome. A test for storage pool deficient platelets. Am J Pathol 1972;68:57-66.
31. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma Jr FJ, Wiekowski MT, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-1598.
32. Tanaka M, Kamata R, Yanagihara K, Sakai R. Suppression of gastric cancer dissemination by ephrin-B1-derived peptide. Cancer Sci 2010;101:87-93.